Related Experiment Videos
Acute colonic pseudo-obstruction associated with interleukin-2 therapy
A B Post1, G W Falk, R M Bukowski
1Department of Gastroenterology, Cleveland Clinic Foundation, Ohio.
The American Journal of Gastroenterology
|October 1, 1991
Summary
A patient with metastatic gastric cancer experienced massive colonic dilatation during recombinant interleukin-2 therapy. This rare gastrointestinal complication, colonic pseudo-obstruction, highlights a potential toxicity of interleukin-2 immunotherapy.
Area of Science:
- Gastroenterology
- Oncology
- Immunotherapy
Background:
- Metastatic gastric carcinoma requires advanced treatment strategies.
- Recombinant interleukin-2 (IL-2) is used in cancer immunotherapy.
- Gastrointestinal side effects are common with IL-2 therapy.
Observation:
- A patient with metastatic gastric cancer developed severe colonic dilatation.
- This occurred during treatment with recombinant IL-2.
- The patient presented with symptoms suggestive of bowel obstruction.
Findings:
- The case report details a previously undocumented complication: colonic pseudo-obstruction.
- This condition mimics a mechanical bowel obstruction but is functional.
- The findings suggest a potential link between IL-2 and colonic motility dysfunction.
Implications:
- Heightened awareness of colonic pseudo-obstruction is crucial for clinicians using IL-2.
- Early recognition and management of this complication can prevent serious outcomes.
- Further research into the mechanisms of IL-2-induced gastrointestinal toxicity is warranted.